CORE LABS INC (CLB)
(Delayed Data from NYSE)
$18.58 USD
-0.01 (-0.05%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $18.58 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Income Statements
Fiscal Year end for Core Laboratories Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 510 | 490 | 470 | 487 | 668 |
Cost Of Goods | 400 | 394 | 368 | 375 | 496 |
Gross Profit | 110 | 96 | 102 | 113 | 173 |
Selling & Adminstrative & Depr. & Amort Expenses | 55 | 55 | 57 | 189 | 76 |
Income After Depreciation & Amortization | 55 | 42 | 45 | -77 | 97 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 13 | 12 | 9 | 14 | 15 |
Pretax Income | 41 | 30 | 36 | -91 | 82 |
Income Taxes | 4 | 10 | 16 | 6 | -12 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 37 | 20 | 20 | -97 | 94 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 8 |
Net Income (GAAP) | 37 | 19 | 20 | -98 | 102 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 70 | 59 | 64 | -56 | 119 |
Depreciation & Amortization (Cash Flow) | 16 | 17 | 19 | 21 | 23 |
Income After Depreciation & Amortization | 55 | 42 | 45 | -77 | 97 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 47.52 | 46.81 | 46.69 | 44.48 | 44.65 |
Diluted EPS Before Non-Recurring Items | 0.71 | 0.57 | 0.71 | 0.80 | 1.79 |
Diluted Net EPS (GAAP) | 0.78 | 0.42 | 0.42 | -2.20 | 2.28 |
Fiscal Year end for Core Laboratories Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 130.58 | 129.64 | 128.21 | 125.34 | 127.88 |
Cost Of Goods | 102.93 | 104.59 | 101.52 | 96.62 | 100.30 |
Gross Profit | 27.65 | 25.05 | 26.69 | 28.73 | 27.59 |
SG&A, R&D, and Dept/Amort Expenses | 11.64 | 16.48 | 12.11 | 14.06 | 8.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | 16.01 | 8.57 | 14.58 | 14.67 | 18.91 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 3.21 | 3.42 | 3.62 | 3.15 | 3.24 |
Pretax Income | 12.80 | 5.15 | 10.96 | 11.53 | 15.67 |
Income Taxes | 3.61 | 1.66 | 8.53 | 2.31 | -7.26 |
Minority Interest | 0.16 | 0.27 | 0.24 | -0.04 | 0.08 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 9.19 | 3.49 | 2.43 | 9.22 | 22.93 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 9.03 | 3.22 | 2.20 | 9.26 | 22.85 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 47.74 | 47.70 | 47.56 | 47.60 | 47.50 |
Diluted EPS Before Non-Recurring Items | 0.22 | 0.13 | 0.19 | 0.22 | 0.23 |
Diluted Net EPS (GAAP) | 0.19 | 0.07 | 0.06 | 0.19 | 0.48 |